Physician profile
Todd E Bush
NPI 1316945835
$2,788.62
in general payments reported to CMS, 2019-2025
26 companies · $30.16 in 2025
The $30.16 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $370 · 2021: $521 · 2022: $482 · 2023: $506 · 2024: $435 · 2025: $30.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $442.55 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $338.36 | 2021-2024 | Azstarys |
| Tris Pharma INC | $283.01 | 2019-2024 | Dyanavel Xr |
| Cranial Technologies, INC | $200.37 | 2019-2024 | Doc Band |
| Glaxosmithkline, LLC. | $177.77 | 2020-2023 | Pediarix, Rotarix, Bexsero |
| Sobi, INC | $174.47 | 2019-2023 | |
| Neos Therapeutics, Lp | $156.28 | 2019-2021 | |
| Adlon Therapeutics L.P. | $106.10 | 2020-2021 | |
| Noven Therapeutics, LLC | $105.17 | 2023-2024 | Xelstrym |
| Kaleo, INC. | $104.91 | 2019-2023 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $99.57 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $97.22 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Abbvie INC. | $84.12 | 2020-2021 | |
| Genentech USA, INC. | $65.52 | 2019-2021 | |
| Pfizer INC. | $58.68 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.72 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $50.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $43.46 | 2022-2023 | Flumist Quadrivalent |
| Jazz Pharmaceuticals INC. | $27.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.38 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.96 | 2020 | |
| Alk-Abello, INC | $16.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.08 | 2021 | |
| Qol Medical, LLC | $14.63 | 2021 | |
| Smith+Nephew, INC. | $13.95 | 2021 | |
| Biomarin Pharmaceutical INC. | $13.41 | 2024 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.